While our manuscript was in revision, two preprints also propose epigenetic mechanisms, EZH2 and phenotypic cell states, as regulators and determinants of NB immune signaling.41 42 Together with our work, this underscores the emerging concept of using epigenetic drugs for targeted immunomodulation of high-risk NBs. The gene discussed is EZH2; the disease is neuroblastoma.